Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 201–300 of 1,002
Stern, M., Ruggeri, L., Mancusi, A., Bernardo, M. E., de Angelis, C., Bucher, C., Locatelli, F., Aversa, F., & Velardi, A. (2008) · Blood · doi:10.1182/blood-2008-01-135285 · Cited by 235
Self-citationHuman natural killer cell deficiencies
Orange, J. S. (2006) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3280106b65 · Cited by 229
Moretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M. C., & Moretta, A. (2011) · Blood · doi:10.1182/blood-2010-08-264085 · Cited by 229
Nivolumab in NSCLC: latest evidence and clinical potential
Sundar, R., Cho, B.-C., Brahmer, J. R., & Soo, R. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014567470 · Cited by 229
“The inhibition of KIR results in NK-cell-mediated antitumor activity [Ruggeri et al. 2002].”
BackgroundImmunosuppression by mesenchymal stromal cells: From culture to clinic
Jones, B. J., & McTaggart, S. J. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.03.006 · Cited by 227
Cooley, S., Xiao, F., Pitt, M., Gleason, M., McCullar, V., Bergemann, T. L., McQueen, K. L., Guethlein, L. A., Parham, P., & Miller, J. S. (2007) · Blood · doi:10.1182/blood-2006-07-036228 · Cited by 226
Treatment of severe autoimmune disease by stem-cell transplantation
Sykes, M., & Nikolic, B. (2005) · Nature · doi:10.1038/nature03728 · Cited by 227
“and the infusion of alloreactive natural killer cell”
BackgroundNext generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
Daher, M., & Rezvani, K. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.013 · Cited by 224
Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
Levy, E. M., Roberti, M. P., & Mordoh, J. (2011) · BioMed Research International · doi:10.1155/2011/676198 · Cited by 219
NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
Thielens, A., Vivier, E., & Romagné, F. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.001 · Cited by 214
Role of Chemokines in the Biology of Natural Killer Cells
Maghazachi, A. A. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_20 · Cited by 216
“Patients with AML receiving KIR/MHC mismatched in the donor/recipient combinations have more than 60% survival rate when compared to less than 5% survival in patients not receiving alloreactive NK cells (Ruggeri et al. 2002).”
BackgroundImmune reconstitution after hematopoietic cell transplantation
Bosch, M., Khan, F. M., & Storek, J. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328353bc7d · Cited by 214
Storb, R., Gyurkocza, B., Storer, B. E., Sorror, M. L., Blume, K., Niederwieser, D., Chauncey, T. R., Pulsipher, M. A., Petersen, F. B., Sahebi, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0247 · Cited by 214
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Becker, P. S. A., Suck, G., Nowakowska, P., Ullrich, E., Seifried, E., Bader, P., Tonn, T., & Seidl, C. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1792-y · Cited by 208
“The discovery of donorderived alloreactive NK cells present in T-cell-depleted HLA haplo-identical grafts for hematopoietic stem cell transplantation (HSCT) was a milestone in the field of NK cell therapy [4, 5].”
BackgroundKillers 2.0: NK cell therapies at the forefront of cancer control
Hodgins, J. J., Khan, S. T., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 217
Hsu, K. C., Gooley, T., Malkki, M., Pinto-Agnello, C., Dupont, B., Bignon, J.-D., Bornhäuser, M., Christiansen, F., Gratwohl, A., Morishima, Y., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.04.008 · Cited by 212
Russo, A., Oliveira, G., Berglund, S., Greco, R., Gambacorta, V., Cieri, N., Toffalori, C., Zito, L., Lorentino, F., Piemontese, S., et al. (2018) · Blood · doi:10.1182/blood-2017-05-780668 · Cited by 208
Sanchez-Correa, B., Valhondo, I., Hassouneh, F., Lopez-Sejas, N., Pera, A., Bergua, J. M., Arcos, M. J., Bañas, H., Casas-Avilés, I., Durán, E., et al. (2019) · Cancers · doi:10.3390/cancers11060877 · Cited by 213
Or, R., Shapira, M. Y., Resnick, I., Amar, A., Ackerstein, A., Samuel, S., Aker, M., Naparstek, E., Nagler, A., & Slavin, S. (2003) · Blood · doi:10.1182/blood-2002-02-0535 · Cited by 210
“The feasibility of controlling CML by immunotherapy mediated by in vitro activated alloreactive T cells (46) and/or NK cells or NKT cells that may mediate more potent anti-tumor effects, occasionally with no GVHD (47), or”
BackgroundAnderson, B. E., McNiff, J. M., Jain, D., Blazar, B. R., Shlomchik, W. D., & Shlomchik, M. J. (2005) · Blood · doi:10.1182/blood-2004-08-3032 · Cited by 207
Self-citationCurrent Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 210
Allogeneic hematopoietic cell transplantation: the state of the art
Gyurkocza, B., Rezvani, A., & Storb, R. F. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.21 · Cited by 202
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., & Rossig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 206
Scoville, S. D., Mundy-Bosse, B. L., Zhang, M. H., Chen, L., Zhang, X., Keller, K. A., Hughes, T., Chen, L., Cheng, S., Bergin, S. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.007 · Cited by 206
“Indeed, the potential translational impact of identifying therapeutic targets that could influence ILC development in human patients warrants further investigation given the accumulating evidence that ILCs are impactful inmultiple disease settings (Munneke et al., 2014; Ruggeri et al., 2002).”
Natural killer cell activation in mice and men: different triggers for similar weapons?
Colucci, F., Di Santo, J. P., & Leibson, P. J. (2002) · Nature Immunology · doi:10.1038/ni0902-807 · Cited by 207
“To date, however, there have been few clinical successe”
BackgroundFerlazzo, G., Morandi, B., D'Agostino, A., Meazza, R., Melioli, G., Moretta, A., & Moretta, L. (2003) · European Journal of Immunology · doi:10.1002/immu.200310004 · Cited by 206
How Do Natural Killer Cells Find Self to Achieve Tolerance?
Yokoyama, W. M., & Kim, S. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.006 · Cited by 206
Cooley, S., McCullar, V., Wangen, R., Bergemann, T. L., Spellman, S., Weisdorf, D. J., & Miller, J. S. (2005) · Blood · doi:10.1182/blood-2005-04-1644 · Cited by 207
“Mean age, y, (range) at transplantation 37 (11-54) 35 (13-52) .”
Tricking the balance: NK cells in anti-cancer immunity
Pahl, J., & Cerwenka, A. (2017) · Immunobiology · doi:10.1016/j.imbio.2015.07.012 · Cited by 205
“…out by the finding that, after haploidentical hematopoietic stem cell transplantation, alloreactive NK cells (generated from the donor graft in the recipient) support graft-versus-tumor effects and reduce leukemia recurrence in patients with acute myeloid leukemia (ALL) (Ruggeri et al., 2002).”
BackgroundEmbryonic and adult stem cell therapy
Brignier, A. C., & Gewirtz, A. M. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.032 · Cited by 199
Björklund, A. T., Carlsten, M., Sohlberg, E., Liu, L. L., Clancy, T., Karimi, M., Cooley, S., Miller, J. S., Klimkowska, M., Schaffer, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3196 · Cited by 200
“In the context of allogeneic HSCT, NK-cell alloreactivity predicted by the absence of KIR ligands in the recipient is associated with targeting of leukemic blasts and improved clinical outcome (34, 35).”
BackgroundMénard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202
“The renaissance of NK cells in tumor immunosurveillance can be attributed to the discovery of stress-induced ligands for NK cell–activating receptors (20) and the relevance of MHC class I/Killer Inhibitory Receptor interactions in mismatched hematopoietic transplants causing NK cell–mediated graft versus leukemia effe…”
BackgroundSimonetta, F., Alvarez, M., & Negrin, R. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00465 · Cited by 200
“At the same time, several preclinical and clinical studies focusing on NK cell alloreactivity in anticancer responses identified donor NK cells as crucial players in preventing cancer relapse after HCT for hematologic malignancies (3, 4).”
BackgroundInfluentialNatural killer cell‐based immunotherapy in cancer: current insights and future prospects
Sutlu, T., & Alici, E. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02121.x · Cited by 200
Parham, P., Norman, P. J., Abi-Rached, L., & Guethlein, L. A. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0266 · Cited by 201
The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity
Ma, S., Yan, J., Barr, T., Zhang, J., Chen, Z., Wang, L.-S., Sun, J. C., Chen, J., Caligiuri, M. A., & Yu, J. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20210279 · Cited by 195
“Adoptive transfer of allogeneic NK cells into leukemia patients can lead to remission (Ruggeri et al., 2002).”
BackgroundAugmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis
Pan, R., Ryan, J., Pan, D., Wucherpfennig, K. W., & Letai, A. (2022) · Cell · doi:10.1016/j.cell.2022.03.030 · Cited by 198
Chester, C., Fritsch, K., & Kohrt, H. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00601 · Cited by 195
“However, in acute myeloid leukemia (AML) patients following haploidentical stem cell transplantation from KIR mismatched donors, the absence of KIR–HLA class I interactions resulted in potent NK cell-mediated antitumor efficacy and increased survival (77, 78).”
BackgroundShah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D. A., Cooper, L. J. N., Decker, W. K., Li, S., Robinson, S. N., Sekine, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076781 · Cited by 199
“Indeed a clinical trial with allogeneic PB-derived NK cells for MM has demonstrated safety and no increase in GVHD [42], though the role of KIR-HLA I incompatibility on NK cell alloreactivity remains to be defined.”
InfluentialYu, J., Heller, G., Chewning, J., Kim, S., Yokoyama, W. M., & Hsu, K. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5977 · Cited by 198
“Interestingly, in HLAmismatched AHSCT donor NK alloreactivity declines within 3 mo following transplant (17), implying a plasticity in NK tolerance dependent more upon the HLA environment of encountered target cells than the HLA phenotype of the NK cell itself (36).”
BackgroundNK cells: a lesson from mismatched hematopoietic transplantation
Velardi, A., Ruggeri, L., Alessandro, Moretta, & Moretta, L. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02284-6 · Cited by 199
Self-citationSavani, B. N., Mielke, S., Adams, S., Uribe, M., Rezvani, K., Yong, A. S. M., Zeilah, J., Kurlander, R., Srinivasan, R., Childs, R., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404892 · Cited by 196
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
Baginska, J., Viry, E., Paggetti, J., Medves, S., Berchem, G., Moussay, E., & Janji, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00490 · Cited by 198
“Mol Cell Proteomics (2010) 9(6):1085–99.”
BackgroundHong, C.-S., Sharma, P., Yerneni, S. S., Simms, P., Jackson, E. K., Whiteside, T. L., & Boyiadzis, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14661-w · Cited by 197
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Lupo, K. B., & Matosevic, S. (2019) · Cancers · doi:10.3390/cancers11060769 · Cited by 196
“Hosokai et al. [65] described the incidence of grade IV GvHD in A/A haplotype patients transplanted from HLA-mismatched donors with KIR haplotype B/x.”
Nowbakht, P., Ionescu, M.-C. S., Rohner, A., Kalberer, C. P., Rossy, E., Mori, L., Cosman, D., De Libero, G., & Wodnar-Filipowicz, A. (2005) · Blood · doi:10.1182/blood-2004-07-2585 · Cited by 196
Shi, J., Tricot, G., Szmania, S., Rosen, N., Garg, T. K., Malaviarachchi, P. A., Moreno, A., DuPont, B., Hsu, K. C., Baxter‐Lowe, L. A., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07340.x · Cited by 194
“Ruggeri et al (2002) first reported that NK cells from KIR-ligand mismatched donors exert a potent anti-leukaemic effect and prevent relapse after haplo-identical transplantation for acute myeloid leukaemia (AML).”
BackgroundMethodInfluentialTakenaka, K., Nishida, T., Asano-Mori, Y., Oshima, K., Ohashi, K., Mori, T., Kanamori, H., Miyamura, K., Kato, C., Kobayashi, N., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.07.019 · Cited by 192
“In general, the NK cellemediated graft-versus-leukemia effect is more prominent in myeloid malignancies than in lymphoid malignancies [37-39], and this could be the reason why a CMV-associated decreased incidence of relapse was observed mainly in patients with AML.”
BackgroundNK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez-Cortegana, C., Tay, A. H. M., Wickström, S., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 189
Veluchamy, J. P., Kok, N., van der Vliet, H. J., Verheul, H. M. W., de Gruijl, T. D., & Spanholtz, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00631 · Cited by 197
“Unlike autologous NK cells, allogeneic NK cells are not restricted by the patient’s tumor’s HLA expression, which is an added advantage to mount an improved anti-tumor effect (38, 39).”
BackgroundIgarashi, T., Wynberg, J., Srinivasan, R., Becknell, B., McCoy, J. P., Takahashi, Y., Suffredini, D. A., Linehan, W. M., Caligiuri, M. A., & Childs, R. W. (2004) · Blood · doi:10.1182/blood-2003-12-4438 · Cited by 195
Wennerberg, E., Kremer, V., Childs, R., & Lundqvist, A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1629-5 · Cited by 192
“Moreover, alloreactive donor NK cells can mediate anti-tumoral effects in patients with acute myeloid leukemia (AML) that undergo haploidentical hematopoietic cell transplantation [11].”
BackgroundRizzieri, D. A., Koh, L. P., Long, G. D., Gasparetto, C., Sullivan, K. M., Horwitz, M., Chute, J., Smith, C., Gong, J. Z., Lagoo, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0953 · Cited by 191
Spanholtz, J., Tordoir, M., Eissens, D., Preijers, F., van der Meer, A., Joosten, I., Schaap, N., de Witte, T. M., & Dolstra, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009221 · Cited by 188
“Generally, the KIR2DL2/DL3/DS2+ subset was present in a higher proportion in all NK cell products analyzed so far, which is in agreement with earlier observations that recovery of KIR2DL2/DL3/DS2+ NK cells is faster compared to the KIR2DL1/DS1+ subset following HSCT [19].”
BackgroundInfluentialPD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Pesce, S., Greppi, M., Grossi, F., Del Zotto, G., Moretta, L., Sivori, S., Genova, C., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01242 · Cited by 187
“Initially, NK cell-based immunotherapy had mainly been exploited to treat hematological malignancies and relied either on the adoptive transfer of NK cells or on NK cells generated from transplanted hematopoietic stem cell to treat high-risk leukemia (35, 36).”
BackgroundImamura, M., Shook, D., Kamiya, T., Shimasaki, N., Chai, S. M. H., Coustan-Smith, E., Imai, C., & Campana, D. (2014) · Blood · doi:10.1182/blood-2014-02-556837 · Cited by 188
de Rham, C., Ferrari-Lacraz, S., Jendly, S., Schneiter, G., Dayer, J.-M., & Villard, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2336 · Cited by 184
“To date, the suitability of KIR as a target of intervention has been suggested by studies of bone marrow transplantation [10-12].”
Zheng, H., Matte-Martone, C., Li, H., Anderson, B. E., Venketesan, S., Sheng Tan, H., Jain, D., McNiff, J., & Shlomchik, W. D. (2008) · Blood · doi:10.1182/blood-2007-08-109678 · Cited by 185
Self-citationNatural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned
Boudreau, J. E., & Hsu, K. C. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.12.001 · Cited by 184
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
Schönberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., Manser, A. R., Uhrberg, M., Verbeek, W., Koschmieder, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3198 · Cited by 181
“Our results might also be considered in this context because NK cells are critical for the graft versus leukemia effect after allogeneic stem cell transplantation (46).”
BackgroundLamers-Kok, N., Panella, D., Georgoudaki, A.-M., Liu, H., Özkazanc, D., Kučerová, L., Duru, A. D., Spanholtz, J., & Raimo, M. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01382-5 · Cited by 178
A new self: MHC-class-I-independent Natural-killer-cell self-tolerance
Kumar, V., & McNerney, M. E. (2005) · Nature Reviews Immunology · doi:10.1038/nri1603 · Cited by 187
“Donor-derived alloreactive NK cells can increase graft-versus-leukaemia responses, decrease graft-versus-host disease and decrease host-versus-graft rejection in the setting of an allogeneic bone-marrow transplant for the treatment of leukaemi”
BackgroundKIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro
Chewning, J. H., Gudme, C. N., Hsu, K. C., Selvakumar, A., & Dupont, B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.854 · Cited by 186
“The present study strongly supports the HLA-KIR ligand incompatibility model as originally presented and applied to HLA class I incompatible, HLA haploidentical donor-recipient pairs (39, 40).”
BackgroundResultSymons, H. J., Leffell, M. S., Rossiter, N. D., Zahurak, M., Jones, R. J., & Fuchs, E. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.11.022 · Cited by 186
“At least 4 models of NK cell alloreactivity (Figure 1) have been proposed to predict HSCT outcomes: (1) KIR ligand incompatibility, or ligand-ligand model [7,11,14-16] (Figure 1A); (2) receptor-ligand model [9] (Figure 1B);”
MethodDahlberg, C. I. M., Sarhan, D., Chrobok, M., Duru, A. D., & Alici, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00605 · Cited by 184
“Less inhibited NK cells could lead to better prognosis and might be the best treatment for a good clinical outcome if GvHD can be avoided (38, 121).”
BackgroundGenetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Kremer, V., Ligtenberg, M. A., Zendehdel, R., Seitz, C., Duivenvoorden, A., Wennerberg, E., Colón, E., Scherman-Plogell, A.-H., & Lundqvist, A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0275-9 · Cited by 178
Klingebiel, T., Cornish, J., Labopin, M., Locatelli, F., Darbyshire, P., Handgretinger, R., Balduzzi, A., Owoc-Lempach, J., Fagioli, F., Or, R., et al. (2010) · Blood · doi:10.1182/blood-2009-03-207001 · Cited by 183
Self-citationBenson, D. M., Cohen, A. D., Jagannath, S., Munshi, N. C., Spitzer, G., Hofmeister, C. C., Efebera, Y. A., Andre, P., Zerbib, R., & Caligiuri, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0304 · Cited by 180
“KIR-ligandmismatchhas been shown tobe a potential determinant of outcome in allogeneic stem cell transplantation in multiple myeloma as in other hematologic malignancies (19, 23).”
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
Granzin, M., Wagner, J., Köhl, U., Cerwenka, A., Huppert, V., & Ullrich, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00458 · Cited by 181
Tumor and viral recognition by natural killer cells receptors
Arnon, T. I., Markel, G., & Mandelboim, O. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.005 · Cited by 178
Targeting NK-cell checkpoints for cancer immunotherapy
Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., López-Díaz de Cerio, A., Cabo, M., López-Botet, M., & Melero, I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.003 · Cited by 182
Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy
Pedroza-Pacheco, I., Madrigal, A., & Saudemont, A. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.2 · Cited by 176
Dalle, J.-H., Menezes, J., Wagner, É., Blagdon, M., Champagne, J., Champagne, M. A., & Duval, M. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000156501.55431.20 · Cited by 180
“It was shown recently that absence of NK cell inhibition by hematopoietic host cells decreases GVHD rate and improves engraftment in some series of adult stem cell transplantation (3,4).”
BackgroundAllorecognition and the alloresponse: clinical implications
Afzali, B., Lechler, R. I., & Hernandez‐Fuentes, M. P. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2007.00834.x · Cited by 179
“The importance of this recognition stems from the fact that in the clinical setting of mismatched hematopoietic stem cell transplantation, donor vs recipient natural killer (NK) cell alloreactivity has been associated with better outcome (53).”
Williams, B. A., Law, A. D., Routy, B., denHollander, N., Gupta, V., Wang, X.-H., Chaboureau, A., Viswanathan, S., & Keating, A. (2017) · Oncotarget · doi:10.18632/oncotarget.19204 · Cited by 179
CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy
Rosenberg, J., & Huang, J. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.11.006 · Cited by 175
“One of the advantages of developing CAR-NK cells over CAR-T cells is that NK cells actually inhibit graft versus host disease (GvHD), and therefore may confer greater safety than T cells [94,95,96,97,98 ,99,100,101].”
BackgroundBoyiadzis, M., Agha, M., Redner, R. L., Sehgal, A., Im, A., Hou, J.-Z., Farah, R., Dorritie, K. A., Raptis, A., Lim, S. H., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.008 · Cited by 178
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Nayyar, G., Chu, Y., & Cairo, M. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00051 · Cited by 177
“NK cells have shown significant alloreactive anti-leukemic effects against liquid tumor cells especially following haploidentical SCT (stem cell transplantation) (17) and the higher NK cell immune reconstitution in the early post allogeneic SCT period has also been demonstrated to be associated with significantly impr…”
BackgroundCook, M. A., Milligan, D. W., Fegan, C. D., Darbyshire, P. J., Mahendra, P., Craddock, C. F., Moss, P. A. H., & Briggs, D. C. (2004) · Blood · doi:10.1182/blood-2003-02-0438 · Cited by 177
“They were divided into lymphoid and myeloid groups, as previous studies had indicated that the KIR effect is more pronounced in patients with myeloid disease.(16-18) Patients in the lymphoid disease group had a slightly lower mean age and were more likely to have been transplanted using a reduced intensity regime.”
BackgroundStern, M., Passweg, J. R., Meyer-Monard, S., Esser, R., Tonn, T., Soerensen, J., Paulussen, M., Gratwohl, A., Klingebiel, T., Bader, P., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.162 · Cited by 176
Allogeneic natural killer cells for refractory lymphoma
Bachanova, V., Burns, L. J., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lindgren, B. R., Cooley, S., Weisdorf, D., & Miller, J. S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0896-z · Cited by 177
Chu, Y., Hochberg, J., Yahr, A., Ayello, J., van de Ven, C., Barth, M., Czuczman, M., & Cairo, M. S. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0114 · Cited by 174
“In contrast, NK cell–based immunotherapy has not been associated with a cytokine-release syndrome in patients; it has been associated with a significant NK versus leukemic effect in the absence of graft-versus-host disease (GvHD) and a significant decrease in leukemia relapse following haploidentical allogeneic stem c…”
BackgroundInfluentialShimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P., Leung, W., & Campana, D. (2012) · Cytotherapy · doi:10.3109/14653249.2012.671519 · Cited by 177
Co‐evolution of NK receptors and HLA ligands in humans is driven by reproduction
Moffett, A., & Colucci, F. (2015) · Immunological Reviews · doi:10.1111/imr.12323 · Cited by 174
“Subsets of donor NK cells expressing inhibitory KIR not engaged by the mismatched host HLA-C allotypes could be sensing the missing self HLA-C and, free from inhibitory constraints, would attack and eliminate residual leukemia cells and help prevent relapse (37).”
BackgroundZhou, X., Di Stasi, A., Tey, S.-K., Krance, R. A., Martinez, C., Leung, K. S., Durett, A. G., Wu, M.-F., Liu, H., Leen, A. M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-551671 · Cited by 172
“18 there is little good evidence for a substantive contribution from a GvL effect of donor T cells [8,9,44-48].”
BackgroundChakraverty, R., & Sykes, M. (2007) · Blood · doi:10.1182/blood-2006-12-022038 · Cited by 173
Sivori, S., Cantoni, C., Parolini, S., Marcenaro, E., Conte, R., Moretta, L., & Moretta, A. (2003) · European Journal of Immunology · doi:10.1002/eji.200324533 · Cited by 173
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease
Negrin, R. S., & Contag, C. H. (2006) · Nature Reviews Immunology · doi:10.1038/nri1879 · Cited by 172
“NK cells have also been observed to lack the capacity to induce GVHD but can have GVL effect”
BackgroundEmerging insights into human health and NK cell biology from the study of NK cell deficiencies
Mace, E. M., & Orange, J. S. (2019) · Immunological Reviews · doi:10.1111/imr.12725 · Cited by 172
Beelen, D. W., Ottinger, H. D., Ferencik, S., Elmaagacli, A. H., Peceny, R., Trenschel, R., & Grosse-Wilde, H. (2005) · Blood · doi:10.1182/blood-2004-04-1441 · Cited by 172
“Advanced disease stages 16/75 (21) 6/42 (14) 2/26 (8) NS*”
BackgroundRomani, L., Bistoni, F., Perruccio, K., Montagnoli, C., Gaziano, R., Bozza, S., Bonifazi, P., Bistoni, G., Rasi, G., Velardi, A., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004762 · Cited by 172
Self-citationMao, Y., van Hoef, V., Zhang, X., Wennerberg, E., Lorent, J., Witt, K., Masvidal, L., Liang, S., Murray, S., Larsson, O., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698027 · Cited by 172
Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self
Ruggeri, L., Aversa, F., Martelli, M. F., & Velardi, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00455.x · Cited by 172
“After host immune suppression, infused alloreactive NK cells home at all lymphohematopoietic sites of the recipient mouse and quickly ablate recipient-type lymphohematopoietic cells (30).”
BackgroundInfluentialSelf-citationClinical utility of natural killer cells in cancer therapy and transplantation
Knorr, D. A., Bachanova, V., Verneris, M. R., & Miller, J. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.002 · Cited by 170
“, KIR ligand mismatch in the graft versus host (GVH) direction) [66].”
Maternal KIR and fetal HLA-C: a fine balance
Chazara, O., Xiong, S., & Moffett, A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0511227 · Cited by 168
“selection remains HLA class I and class II matching [149].”
BackgroundChimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
Hu, Y., Tian, Z.-G., & Zhang, C. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.125 · Cited by 169
Dong, H., Adams, N. M., Xu, Y., Cao, J., Allan, D. S. J., Carlyle, J. R., Chen, X., Sun, J. C., & Glimcher, L. H. (2019) · Nature Immunology · doi:10.1038/s41590-019-0388-z · Cited by 172
Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
Gras Navarro, A., Björklund, A. T., & Chekenya, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00202 · Cited by 167
“This mechanism has been shown to induce potent NK cell alloreactivity and to mediate graft versus malignancy effect but not treatment limiting GvHD in some leukemia types (189, 191).”
Background
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.